Cardiology · 2001 · 12 citations · 22 references
MedicineCardiologyPharmacologyCardiovascular PharmacotherapyClinical PharmacologyExperimental PharmacologyAntiarrhythmic TherapyCardiac ArrhythmiasCardiac MedicationsCardiac PharmacotherapyCardiac PhysiologyCardiovascular PharmacologyAntiarrhythmic Drug EffectsAntiarrhythmic PharmacologyArrhythmogenic MechanismsPharmacodynamics Of Antiarrhythmic DrugsVentricular Arrhythmia Pharmacotherapy
We documented chronic ventricular arrhythmias in a first group of 58 rats after myocardial infarction (MI), then assessed the effects of spironolactone and fosinopril on morphological indexes and arrhythmias in a second group (n = 33). Rats underwent Holter monitoring at 2 months after MI. Treatment was randomly given from 1 until 4 months after MI: placebo in 12 rats (P), fosinopril in 9 (F) and spironolactone + fosinopril in 12 (SF). The score of ventricular premature beats (VPBs) was related to the MI size and the delay from MI (p < 0.01). VPB's reduction/increase required to demonstrate anti/pro-arrhythmic effects were 55 and 59%. Mass indexes were lower in F and SF (p = 0.01). VPB's difference (4 months vs. 1) was positive in P, significantly lower in F and negative in SF (p = 0.04). In this relevant model of spontaneous and chronic ventricular arrhythmias, SF association did not increase mortality but lowered the arrhythmic score.
22
Lars Køber, Christian Torp‐Pedersen, Jan E. Carlsen et al. · New England Journal of Medicine · 1995 · 1.8K citations · Full text
Medicine, Cardiology, Pharmacology +14
Myocardial infarct size and ventricular function in rats.
Marc A. Pfeffer, J M Pfeffer, Michael C. Fishbein et al. · Circulation Research · 1979 · 1.3K citations
Medicine, Cardiology, Physiology +17